Global Research PartnershipsCreate free account
Industry Collaboration Index

Industry Collaboration Index 2026 · University profile

The University of Texas Medical Branch at Galveston

United States · North America

#611World rank of 1,038
44.7ICI scoreout of 100
#150National rank, of 203 in United States
#171Regional rank, of 231 in North America
390Verified industry works, 2021 to 2025
239Company groups worked with (66 on two or more works)

The University of Texas Medical Branch at Galveston is ranked #611 of 1,038. Its strongest pillar is durability (53): 23 of its company groups are sustained partners (five or more joint works in three or more of the five years). It is held back most by breadth (19): partners concentrated in a few research fields; and by scale (50): a network of 66 company groups on two or more joint works.

Research Collaboration Index 2026: #815 of 1,195 · View the RCI profile →

Why this position

Four pillars, as percentiles

Co-creation30% of the score
51

How often it co-authors with companies, compared with what its own mix of research fields would predict; size makes no difference. 390 verified works against about 390 expected for its fields (1.00 times the expected rate).

Durability20% of the score
53

How much of its industry work sits in sustained partnerships with the same company group. 23 sustained partnerships: five or more joint works in three or more of the five years.

Scale30% of the score
50

The size of its industry network: company groups on two or more works, sustained partnerships, and its place in the worldwide network of universities and companies. 66 company groups on two or more joint works; 23 sustained partnerships.

Breadth20% of the score
19

How varied its partners are, judged by each company's main research field. Measured across the main research fields of all the company groups it worked with.

Each pillar is a percentile among the 1,038 ranked universities: a value of 80 means a higher value than about 80 in every 100 of them. The ICI score (44.7) is the weighted average of the four percentiles. Rank 611 of 1,038 overall; 150 of 203 in United States; 171 of 231 in North America. Standing bands: Platinum for ranks 1 to 100, Gold 101 to 300, Silver 301 to 600. How the index is built →

In numbers

The evidence behind the position

4.3%of its 9,139 research works in 2021 to 2025 were co-authored with a verified company
1.00Industry co-authorship rate: 1.00 times what its mix of research fields would predict (390 verified works; about 390 expected)
23sustained partnerships: the same company group on five or more joint works in three or more of the five years

In United States

150 of 203 ranked universities in United States

  1. #148 Missouri University of Science and Technology world #604, score 44.9
  2. #149 University of Vermont world #605, score 44.9
  3. #150 The University of Texas Medical Branch at Galveston world #611, score 44.7
  4. #151 Utah State University world #617, score 44.2
  5. #152 SUNY Upstate Medical University world #622, score 44.0

All ranked universities →   North America: 171 of 231 →

Where it works with industry

Sector strengths

Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.

Sector positions

#605 of 638Pharmaceuticals and Therapeutics27 verified works in the sector
Pharmaceuticals and Therapeutics
27#605 of 638
Medical Technology and Digital Health
11under 20 works
Biotechnology and Advanced Therapies
7under 20 works
Advanced Materials and Nanotechnology
1under 20 works
Climate, Environment and Sustainability
1under 20 works
Not in any of the 21 sectors
343counted in the overall index

47 of its 390 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.

Who it works with

Company partners, 2021 to 2025

The University of Texas Medical Branch at Galveston co-authored verified work with 239 company groups, consortium papers aside: 66 of them on two or more works, and 23 as sustained partners.

The largest 12 of its 239 company groups, by joint works

Company groupBased inCompany's main research fieldJoint worksYears with a joint work
KBRUnited StatesEngineering285 of 5
PfizerUnited StatesMedicine20.55 of 5
BioNTechGermanyMedicine155 of 5
Gilead SciencesUnited StatesMedicine115 of 5
Biomed ProtectionUnited StatesMedicine105 of 5
Merck & Co. (MSD)United StatesMedicine94 of 5
Moderna TherapeuticsUnited StatesMedicine95 of 5
Mapp BiopharmaceuticalUnited StatesMedicine94 of 5
GlaxoSmithKlineUnited KingdomMedicine8.55 of 5
Integral MolecularUnited StatesMedicine73 of 5
EmmesUnited StatesMedicine73 of 5
ZalgenUnited StatesMedicine74 of 5

A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.

Examples of its work with industry

Most-cited verified joint works

Its most-cited verified works with 30 or fewer authors, leaving out guidelines and consensus statements. Citation counts are those of the open scholarly record at harvest. Each title links to the work.

Over time

Verified industry works by year

98.52021
64.52022
742023
72.52024
80.52025

2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.

Clinical trials (reported, not scored)

6 industry-partnered clinical trials

Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.

Examples:

  • NCT07221097 Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses with BioFire Defense LLC, 2025
  • NCT06799013 Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever with HDT Bio, 2025
  • NCT06740253 Safety and Acceptability Study of a Placebo Antibody-Based Nonhormonal Contraceptive Intravaginal Ring with Mucommune, LLC., 2025
  • NCT06737432 Respiratory Knowledge Portal Computer and Phone Application to Improve Quality of Mechanical Ventilation by Reducing the Number of Ventilator Associated Events, Injury Created by the Ventilator and Unsafe Setting of Alarms. with Vyaire Medical, 2024
  • NCT05112640 Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery with Cooper Companies, 2021
  • NCT04974567 Tear Based Sample Collection Breast Cancer Detection with Namida Lab, 2021

Evidence checked

569 verified company links

Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 310 of 879 candidate links were set aside.

Why links were set aside
  • 155 company name not written in the author's affiliation
  • 33 part of a university or public institute's own unit
  • 33 ordinary-word name without a company suffix
  • 20 a place or common word that failed its stricter rule
  • 15 excluded after hand audit: Scripps Research is a non-profit research institute, not a company
  • 9 excluded after hand audit: Matched from social media handles in affiliation text
  • 45 for other reasons: smaller hand-audit findings, and links the current open record no longer supports

If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.

GRP Partnership Intelligence Platform

Where The University of Texas Medical Branch at Galveston's collaboration could go next

This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.

Request first access →  See what is inside →

The platform cannot move any university's position, band or score.

The other GRP index

Research Collaboration Index

In the Research Collaboration Index 2026, The University of Texas Medical Branch at Galveston ranks #815 of 1,195. It measures the whole research network, not only industry.

View the RCI profile →

Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.